XML 78 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue (Disaggregation of Revenue by Product) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disaggregation of Revenue [Line Items]      
Revenues $ 28,318.4 $ 24,539.8 $ 22,319.5
U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 16,811.0 14,229.3 12,722.6
Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 11,507.4 10,310.5 9,596.8
Diabetes | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 8,719.3 7,909.1 7,529.5
Diabetes | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 4,468.8 3,925.3 3,602.6
Trulicity® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 4,914.4 3,835.9 3,155.2
Trulicity® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,557.6 1,232.2 972.7
Humalog® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,320.7 1,485.6 1,669.7
Humalog® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,132.3 1,140.3 1,151.0
Humulin® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 832.9 866.4 879.7
Humulin® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 389.6 393.2 410.4
Jardiance®      
Disaggregation of Revenue [Line Items]      
Revenues 1,490.8 1,153.8 944.2
Jardiance® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 807.3 620.8 565.9
Jardiance® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 683.5 533.0 378.3
Basaglar®      
Disaggregation of Revenue [Line Items]      
Revenues 892.5 1,124.4 1,112.6
Basaglar® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 588.3 842.3 876.2
Basaglar® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 304.2 282.1 236.3
Trajenta®      
Disaggregation of Revenue [Line Items]      
Revenues 372.5 358.5 590.6
Trajenta® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 82.1 95.6 224.8
Trajenta® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 290.4 263.0 365.8
Other Diabetes | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 173.6 162.5 158.0
Other Diabetes | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 111.2 81.5 88.1
Oncology | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 3,028.8 2,792.1 2,608.5
Oncology | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 2,712.5 2,527.2 2,005.9
Alimta® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,233.9 1,265.3 1,219.5
Alimta® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 827.5 1,064.7 896.4
Verzenio® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 834.9 618.2 454.8
Verzenio® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 515.0 294.4 124.9
Cyramza® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 358.1 381.9 335.3
Cyramza® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 674.8 650.8 589.9
Erbitux® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 481.8 480.1 487.9
Erbitux® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 66.4 56.3 55.4
Tyvyt®      
Disaggregation of Revenue [Line Items]      
Revenues 418.1 308.7 134.0
Tyvyt® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 0.0 0.0 0.0
Tyvyt® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 418.1 308.7 134.0
Other Oncology | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 120.1 46.6 111.0
Other Oncology | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 210.7 152.3 205.3
Immunology | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,881.8 1,372.3 1,059.0
Immunology | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,479.0 1,089.6 734.3
Taltz® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,542.4 1,288.5 1,016.8
Taltz® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 670.4 500.0 349.6
Olumiant®      
Disaggregation of Revenue [Line Items]      
Revenues 1,115.1 638.9 426.9
Olumiant® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 324.1 63.8 42.2
Olumiant® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 791.0 575.0 384.7
Other Immunology | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 15.3 20.0 0.0
Other Immunology | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 17.6 14.6 0.0
Neuroscience | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 614.8 487.3 356.5
Neuroscience | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,283.7 1,344.0 1,366.4
Cymbalta® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 38.7 42.1 49.6
Cymbalta® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 542.8 725.6 675.8
Emgality® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 434.5 325.9 154.9
Emgality® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 142.7 37.0 7.7
Zyprexa® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 39.6 46.1 41.0
Zyprexa® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 390.7 360.5 377.6
Other Neuroscience | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 102.0 73.2 111.0
Other Neuroscience | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 207.5 220.9 305.3
Other | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 2,566.4 1,668.4 1,169.1
Other | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,563.5 1,424.4 1,887.7
COVID-19 Antibodies | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 1,978.0 850.0 0.0
COVID-19 Antibodies | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 261.4 21.2 0.0
Forteo® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 441.6 510.3 645.5
Forteo® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 360.3 536.0 759.1
Cialis® | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 10.6 61.8 231.7
Cialis® | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 707.9 545.4 658.8
Other | U.S.      
Disaggregation of Revenue [Line Items]      
Revenues 136.1 246.4 291.9
Other | Outside U.S.      
Disaggregation of Revenue [Line Items]      
Revenues $ 233.9 $ 321.8 $ 469.7